# A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

> **NCT04123626** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ProQR Therapeutics** · enrollment: 11 (actual)

## Conditions studied

- Autosomal Dominant Retinitis Pigmentosa
- Eye Diseases
- Eye Diseases, Hereditary
- Retinal Dystrophies
- Retinal Disease
- Retinitis
- Vision Tunnel
- Vision Disorders

## Interventions

- **DRUG:** QR-1123
- **OTHER:** Sham procedure

## Key facts

- **NCT ID:** NCT04123626
- **Lead sponsor:** ProQR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-07
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123626, "A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04123626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*